Looking at the Levels: Examining the Nuances of Tiered Antiretroviral Therapy (ART) Adherence among Women with HIV in Canada

Cathy Puskas¹, Neora Pick^{2,3}, Allison Carter^{1,4}, Lu Wang¹, Mona Loutfy^{5,6}, Alexandra de Pokomandy^{7,8}, Kathleen Webster⁴, Rebecca Gormley^{1,4}, Angela Kaida¹, on behalf of the CHIWOS Research Team

1. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; 2. Oak Tree Clinic, BC Women's Hospital, Vancouver, BC, Canada; 3. Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, BC, Canada; 4. Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; 5. Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; 6. Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada; 7. Chronic Viral Illness Service, McGill University Health Centre, Montreal, Quebec, Canada

BACKGROUND

- Challenges to optimal ART adherence are gendered and affected by sociodemographic and psychosocial factors.
- Recognizing that women living with HIV (WLWH) are not a homogenous group, we measured ART adherence among women living with HIV using standard (≥95%) and tiered levels to explore associations with viral suppression and psychosocial correlates.
- This study identifies areas and services to support ART adherence among a diverse community of women living with HIV in Canada.

METHODS

- We analyzed survey data from the community-collaborative Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS) collected between August 2013 and May 2015.
- Among women reporting currently receiving ART, we measured self-reported ART adherence in the previous month (Walsh Visual Analog Scale) using two definitions of adherence: dichotomized (≥95% of pills taken versus <95%) and tiered (≥95%, 80-95%, 50-80%, and <50% of pills taken).
- Viral suppression was assessed as undetectable (<50 copies/mL) versus detectable via a validated self-reported measure.
- Multivariable models were developed using logistic regression (dichotomized adherence) and ordinal logistic regression (tiered adherence; sociodemographic and psychosocial models).

Table 1: Bivariate analysis of tiered adherence categories (n=1178).

Variable	≥95% Adherence (n=866) n (%) or Median (Q1-Q3)	80-95% Adherence (n=194) n (%) or Median (Q1-Q3)	50-80% Adherence (n=79) n (%) or Median (Q1-Q3)	<50% Adherence (n=39) n (%) or Median (Q1-Q3)	p-value
Age at interview	45 (37-52)	43 (36-50)	42 (36-49)	41 (32-48)	0.028
Ethnicity					0.003
Indigenous	151 (17%)	54 (28%)	20 (25%)	7 (18%)	
African/Caribbean/Black	271 (31%)	65 (34%)	21 (27%)	19 (49%)	
White	375 (43%)	65 (34%)	28 (35%)	11 (28%)	
Other	69 (8%)	10 (5%)	10 (13%)	2 (5%)	
Food Security					0.001
Secure	351 (41%)	66 (34%)	17 (22%)	10 (26%)	
Insecure	510 (59%)	127 (65%)	62 (78%)	29 (74%)	
Incarceration					< 0.001
Never	571 (66%)	108 (56%)	37 (47%)	28 (72%)	
Not in past year	262 (30%)	64 (33%)	29 (37%)	7 (18%)	
Last year	32 (4%)	21 (11%)	12 (15%)	4 (10%)	
Injection Drug Use					0.036
Never	590 (68%)	117 (60%)	48 (61%)	29 (74%)	
Not currently	207 (24%)	55 (28%)	18 (23%)	6 (15%)	
Currently	54 (6%)	20 (10%)	11 (14%)	4 (10%)	
Perception of care from doctor as women-centred					0.067
Agree	486 (56%)	97 (50%)	34 (43%)	24 (62%)	
Neither agree nor disagree/ disagree	359 (41%)	92 (47%)	42 (53%)	14 (36%)	
Experienced Violence as an Adult					0.005
No	151 (17%)	18 (9%)	5 (6%)	4 (10%)	
Yes	658 (76%)	154 (79%)	70 (89%)	26 (67%)	
CES-D Depression Scale					0.006
No symptoms (<10)	447 (52%)	81 (42%)	29 (37%)	13 (33%)	
Symptoms (≥10)	390 (45%)	103 (53%)	42 (53%)	25 (64%)	
HIV Stigma Support	55 (40-68)	58 (43-73)	60 (50-80)	60 (45-75)	0.004
Personalized Stigma	18 (10-25)	18 (13-25)	23 (15-29)	20 (15-28)	0.041
Negative Self-Image	8 (0-15)	8 (5-18)	10 (8-20)	10 (5-20)	0.001
Resilience Scale	65 (60-69)	61 (56-66)	61 (57-65)	60 (54-67)	<0.001

Note: Responses "Don't know" and "Prefer not to answer" are not shown in this table, however they were included in analyses. Food security was based on a shortened CCHS Household Food Security Survey; food insecurity was defined as ever experiencing food insufficiency or lack of dietary diversity. Incarceration includes both provincial and/or federal incarceration. Experience of depressive symptoms was defined using the modified 10-item CES-D Depression Scale, with a score of 10 or higher indicating the presence of significant depressive symptoms. Personalized HIV-related stigma is the experienced stigma subscale of the Berger Stigma Scale, short form; higher scores indicate higher stigma. Negative self-image is the internalized stigma subscale of the Berger Stigma Scale, short form; higher scores indicate higher stigma. Resilience scale, 10-item scale with higher scores indicating higher resilience.

RESULTS

- Of 1178 women included, 73.5% reported ≥95% adherence, 16.5% reported 80-95%, 6.7% reported 50-80%, and 3.3% reported <50%. Higher adherence (dichotomized and tiered) was associated with viral suppression (p<0.001), however 89% of those reporting 80-95% adherence achieved viral suppression (not shown).
- <u>Sociodemographic model of tiered adherence</u>: food insecurity versus secure (adjusted odds ratio [AOR]: 0.73; 95% confidence interval [CI]: 0.54-0.97), incarceration within the past year versus never (AOR: 0.32; 95% CI: 0.19-0.55) were independently associated with lowered adherence.
- <u>Psychosocial model of tiered adherence</u>: violence experienced as an adult versus no (AOR: 0.53; 95% CI: 0.34-0.83), and negative self-image (AOR: 0.98; 95% CI: 0.96-1.00) were independently associated with lowered adherence, while high resilience scores were associated with higher adherence (AOR: 1.04; 95% CI: 1.02-1.06).
- A caveat to this trend was observed among women with adherence <50%, who often showed fewer markers of marginalization relative to the 50-80% adherence category.

Table 2: Multivariable analyses of variables associated with increased adherence (n=1178). Note: Sociodemographic and psychosocial models are discrete and separate models.

Variable	Univariable Analysis ≥95% versus lower adherence OR (95% CI)	p-value	Multivariable Analysis ≥95% versus lower adherence AOR (95% CI)	p-value
Sociodemographic Model				
Age at interview (per 1 year increase)	1.02 (1.01 to 1.03)	0.002	1.02 (1.01 to 1.03)	0.006
Ethnicity		0.005		0.059
Indigenous	Reference		Reference	
African/Caribbean/Black	1.32 (0.93 to 1.86)		0.93 (0.61 to 1.43)	
White	1.85 (1.32 to 2.61)		1.46 (1.00 to 2.12)	
Other	1.54 (0.90 to 2.64)		1.18 (0.66 to 2.12)	
Food Security		< 0.001		0.033
Secure	Reference		Reference	
Insecure	0.60 (0.46 to 0.79)		0.73 (0.54 to 0.97)	
Incarceration		<0.001		< 0.001
Never	Reference		Reference	
Not in past year	0.81 (0.61 to 1.08)		0.78 (0.55 to 1.11)	
Last year	0.28 (0.18 to 0.46)		0.32 (0.19 to 0.55)	
Injection Drug Use		0.013		
Never	Reference			
Not currently	0.90 (0.66 to 1.22)			
Currently	0.52 (0.33 to 0.80)			
Perception of care from doctor as women-centred				
Agree	Reference	0.066	Reference	0.084
Neither agree nor disagree/disagree	0.78 (0.60 to 1.02)		0.79 (0.60 to 1.03)	
Psychosocial Model				
Experienced Violence as an Adult				
No	Reference	0.001	Reference	0.006
Yes	0.47 (0.31 to 0.73)		0.53 (0.34 to 0.83)	
CES-D Depression Scale		0.001		
No symptoms (<10)	Reference			
Symptoms (≥10)	0.62 (0.48 to 0.82)			
HIV Stigma Support	0.99 (0.98 to 1.00)	< 0.001		
Personalized Stigma	0.98 (0.97 to 1.00)	0.022		
Negative Self-Image	0.97 (0.96 to 0.98)	<0.001	0.98 (0.96 to 1.00)	0.031
Resilience Scale	1.05 (1.03 to 1.06)	<0.001	1.04 (1.02 to 1.06)	<0.001
OR, odds ratio; CI, confidence interval; AOR, adjust Continuous variables report change in adherence re				

DISCUSSION

- Analyses of tiered adherence allows a nuanced identification of gendered and social risk factors for non-maximal adherence among WLWH.
- Addressing marginalization, particularly in relation to food security, incarceration, and experienced violence, among WLWH may increase ART adherence.

Acknowledgments We gratefully acknowledge everyone involved for their invaluable contributions to the study. Thank you to all the women living with HIV involved in this study; the PIs, Coordinators, Peer Research Associates, and all the Coinvestigators and Collaborators; the Steering Committee, Community Advisory Boards, and Aboriginal Advisory Board; Our funders: CIHR Institute of Gender and Health, the CTN, and OHTN; Our affiliated studies: CANOC, REACH & OCS; and all of our partners for supporting the study!































